APO Research
Talk to an analyst

APO RESEARCH · REPORT

Semi-Solid Dosage Form

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Semi-Solid Dosage Form Market Outlook and Growth Opportunities 2026

30 December 2025213 pages

Choose your research edition.

Industry ResearchSemi-Solid Dosage Form Industry Research Report 2026148 pages · $2,950 USDIndustry Growth & TrendsGlobal Semi-Solid Dosage Form Industry Growth and Trends Forecast to 2032124 pages · $3,450 USDMarket StructureGlobal Semi-Solid Dosage Form Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Semi-Solid Dosage Form Market Outlook and Growth Opportunities 2026213 pages · $4,250 USDMarket Analysis & ForecastGlobal Semi-Solid Dosage Form Market Analysis and Forecast 2026-2032215 pages · $4,950 USD

Market perspective

The global Semi-Solid Dosage Form market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Semi-Solid Dosage Form is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Semi-Solid Dosage Form is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Semi-Solid Dosage Form is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Semi-Solid Dosage Form market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Semi-Solid Dosage Form market include Aclaris Therapeutics, Inc., Akorn Inc. (US), Allergan plc, Almirall, S.A, Bausch Health Companies, Biofrontera, Inc., Cipla Ltd, Crescita Therapeutics Inc. and Crown Laboratories Inc., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Semi-Solid Dosage Form market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Semi-Solid Dosage Form and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Semi-Solid Dosage Form sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Semi-Solid Dosage Form market size, projected growth trends, production technologies, key applications, and end-use industries.

Semi-Solid Dosage Form Segment by Company

Aclaris Therapeutics, Inc.

Akorn Inc. (US)

Allergan plc

Almirall, S.A

Bausch Health Companies

Biofrontera, Inc.

Cipla Ltd

Crescita Therapeutics Inc.

Crown Laboratories Inc.

Encore Dermatology, Inc.

Glenmark Pharmaceuticals

Hisamitsu Pharmaceutical

Ingenus Pharmaceuticals

LEO Pharma

Mylan N.V.

Novartis AG

Perrigo Pharma

Taro Pharmaceutical Industries Ltd.

Teligent Pharma

Bayer AG

GlaxoSmithKline plc

Merck & Co

Johnson & Johnson

Nestlé SA

Sun Pharmaceuticals

Semi-Solid Dosage Form Segment by Type

Ointments

Gels

Others

Semi-Solid Dosage Form Segment by Application

Nasal Cavity

Skin

Vaginal Cavity

Rectal Cavity

Others

Semi-Solid Dosage Form Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Semi-Solid Dosage Form status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Semi-Solid Dosage Form market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Semi-Solid Dosage Form significant trends, drivers, influence factors in global and regions.

6. To analyze Semi-Solid Dosage Form competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Semi-Solid Dosage Form market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Semi-Solid Dosage Form and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Semi-Solid Dosage Form.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Semi-Solid Dosage Form market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Semi-Solid Dosage Form industry.

Chapter 3: Detailed analysis of Semi-Solid Dosage Form manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Semi-Solid Dosage Form in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Semi-Solid Dosage Form in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Semi-Solid Dosage Form Industry Trends Table 2. Semi-Solid Dosage Form Industry Drivers Table 3. Semi-Solid Dosage Form Industry Opportunities and Challenges Table 4. Semi-Solid Dosage Form Industry Restraints Table 5. Global Semi-Solid Dosage Form Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Semi-Solid Dosage Form Revenue Share by Company (2021-2026) Table 7. Global Semi-Solid Dosage Form Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Semi-Solid Dosage Form Sales Volume Share by Company (2021-2026) Table 9. Global Semi-Solid Dosage Form Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Semi-Solid Dosage Form Company Ranking, (2024-2026) & (USD Million) Table 11. Global Semi-Solid Dosage Form Key Company Manufacturing Base & Headquarters Table 12. Global Semi-Solid Dosage Form Company, Product Type & Application Table 13. Global Semi-Solid Dosage Form Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Semi-Solid Dosage Form by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Ointments Table 18. Significant Companies of Gels Table 19. Significant Companies of Others Table 20. Global Semi-Solid Dosage Form Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 21. Global Semi-Solid Dosage Form Sales Volume by Type (2021-2026) & (K Units) Table 22. Global Semi-Solid Dosage Form Sales Volume by Type (2027-2032) & (K Units) Table 23. Global Semi-Solid Dosage Form Sales Volume Share by Type (2021-2026) Table 24. Global Semi-Solid Dosage Form Sales Volume Share by Type (2027-2032) Table 25. Global Semi-Solid Dosage Form Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Semi-Solid Dosage Form Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global Semi-Solid Dosage Form Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global Semi-Solid Dosage Form Sales Value Share by Type (2021-2026) Table 29. Global Semi-Solid Dosage Form Sales Value Share by Type (2027-2032) Table 30. Significant Companies of Nasal Cavity Table 31. Significant Companies of Skin Table 32. Significant Companies of Vaginal Cavity Table 33. Significant Companies of Rectal Cavity Table 34. Significant Companies of Others Table 35. Global Semi-Solid Dosage Form Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 36. Global Semi-Solid Dosage Form Sales Volume by Application (2021-2026) & (K Units) Table 37. Global Semi-Solid Dosage Form Sales Volume by Application (2027-2032) & (K Units) Table 38. Global Semi-Solid Dosage Form Sales Volume Share by Application (2021-2026) Table 39. Global Semi-Solid Dosage Form Sales Volume Share by Application (2027-2032) Table 40. Global Semi-Solid Dosage Form Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 41. Global Semi-Solid Dosage Form Sales Value by Application (2021-2026) & (US$ Million) Table 42. Global Semi-Solid Dosage Form Sales Value by Application (2027-2032) & (US$ Million) Table 43. Global Semi-Solid Dosage Form Sales Value Share by Application (2021-2026) Table 44. Global Semi-Solid Dosage Form Sales Value Share by Application (2027-2032) Table 45. Global Semi-Solid Dosage Form Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 46. Global Semi-Solid Dosage Form Sales by Region (2021-2026) & (K Units) Table 47. Global Semi-Solid Dosage Form Sales Market Share by Region (2021-2026) Table 48. Global Semi-Solid Dosage Form Sales by Region (2027-2032) & (K Units) Table 49. Global Semi-Solid Dosage Form Sales Market Share by Region (2027-2032) Table 50. Global Semi-Solid Dosage Form Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 51. Global Semi-Solid Dosage Form Sales Value by Region (2021-2026) & (US$ Million) Table 52. Global Semi-Solid Dosage Form Sales Value Share by Region (2021-2026) Table 53. Global Semi-Solid Dosage Form Sales Value by Region (2027-2032) & (US$ Million) Table 54. Global Semi-Solid Dosage Form Sales Value Share by Region (2027-2032) Table 55. Global Semi-Solid Dosage Form Market Average Price (US$/Unit) by Region (2021-2026) Table 56. Global Semi-Solid Dosage Form Market Average Price (US$/Unit) by Region (2027-2032) Table 57. Global Semi-Solid Dosage Form Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 58. Global Semi-Solid Dosage Form Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Semi-Solid Dosage Form Sales by Country (2021-2026) & (K Units) Table 60. Global Semi-Solid Dosage Form Sales Market Share by Country (2021-2026) Table 61. Global Semi-Solid Dosage Form Sales by Country (2027-2032) & (K Units) Table 62. Global Semi-Solid Dosage Form Sales Market Share by Country (2027-2032) Table 63. Global Semi-Solid Dosage Form Sales Value by Country (2021-2026) & (US$ Million) Table 64. Global Semi-Solid Dosage Form Sales Value Market Share by Country (2021-2026) Table 65. Global Semi-Solid Dosage Form Sales Value by Country (2027-2032) & (US$ Million) Table 66. Global Semi-Solid Dosage Form Sales Value Market Share by Country (2027-2032) Table 67. Aclaris Therapeutics, Inc. Company Information Table 68. Aclaris Therapeutics, Inc. Business Overview Table 69. Aclaris Therapeutics, Inc. Semi-Solid Dosage Form Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 70. Aclaris Therapeutics, Inc. Semi-Solid Dosage Form Product Portfolio Table 71. Aclaris Therapeutics, Inc. Recent Development Table 72. Akorn Inc. (US) Company Information Table 73. Akorn Inc. (US) Business Overview Table 74. Akorn Inc. (US) Semi-Solid Dosage Form Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 75. Akorn Inc. (US) Semi-Solid Dosage Form Product Portfolio Table 76. Akorn Inc. (US) Recent Development Table 77. Allergan plc Company Information Table 78. Allergan plc Business Overview Table 79. Allergan plc Semi-Solid Dosage Form Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 80. Allergan plc Semi-Solid Dosage Form Product Portfolio Table 81. Allergan plc Recent Development Table 82. Almirall, S.A Company Information Table 83. Almirall, S.A Business Overview Table 84. Almirall, S.A Semi-Solid Dosage Form Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 85. Almirall, S.A Semi-Solid Dosage Form Product Portfolio Table 86. Almirall, S.A Recent Development Table 87. Bausch Health Companies Company Information Table 88. Bausch Health Companies Business Overview Table 89. Bausch Health Companies Semi-Solid Dosage Form Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 90. Bausch Health Companies Semi-Solid Dosage Form Product Portfolio Table 91. Bausch Health Companies Recent Development Table 92. Biofrontera, Inc. Company Information Table 93. Biofrontera, Inc. Business Overview Table 94. Biofrontera, Inc. Semi-Solid Dosage Form Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. Biofrontera, Inc. Semi-Solid Dosage Form Product Portfolio Table 96. Biofrontera, Inc. Recent Development Table 97. Cipla Ltd Company Information Table 98. Cipla Ltd Business Overview Table 99. Cipla Ltd Semi-Solid Dosage Form Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. Cipla Ltd Semi-Solid Dosage Form Product Portfolio Table 101. Cipla Ltd Recent Development Table 102. Crescita Therapeutics Inc. Company Information Table 103. Crescita Therapeutics Inc. Business Overview Table 104. Crescita Therapeutics Inc. Semi-Solid Dosage Form Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 105. Crescita Therapeutics Inc. Semi-Solid Dosage Form Product Portfolio Table 106. Crescita Therapeutics Inc. Recent Development Table 107. Crown Laboratories Inc. Company Information Table 108. Crown Laboratories Inc. Business Overview Table 109. Crown Laboratories Inc. Semi-Solid Dosage Form Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 110. Crown Laboratories Inc. Semi-Solid Dosage Form Product Portfolio Table 111. Crown Laboratories Inc. Recent Development Table 112. Encore Dermatology, Inc. Company Information Table 113. Encore Dermatology, Inc. Business Overview Table 114. Encore Dermatology, Inc. Semi-Solid Dosage Form Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 115. Encore Dermatology, Inc. Semi-Solid Dosage Form Product Portfolio Table 116. Encore Dermatology, Inc. Recent Development Table 117. Glenmark Pharmaceuticals Company Information Table 118. Glenmark Pharmaceuticals Business Overview Table 119. Glenmark Pharmaceuticals Semi-Solid Dosage Form Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 120. Glenmark Pharmaceuticals Semi-Solid Dosage Form Product Portfolio Table 121. Glenmark Pharmaceuticals Recent Development Table 122. Hisamitsu Pharmaceutical Company Information Table 123. Hisamitsu Pharmaceutical Business Overview Table 124. Hisamitsu Pharmaceutical Semi-Solid Dosage Form Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 125. Hisamitsu Pharmaceutical Semi-Solid Dosage Form Product Portfolio Table 126. Hisamitsu Pharmaceutical Recent Development Table 127. Ingenus Pharmaceuticals Company Information Table 128. Ingenus Pharmaceuticals Business Overview Table 129. Ingenus Pharmaceuticals Semi-Solid Dosage Form Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 130. Ingenus Pharmaceuticals Semi-Solid Dosage Form Product Portfolio Table 131. Ingenus Pharmaceuticals Recent Development Table 132. LEO Pharma Company Information Table 133. LEO Pharma Business Overview Table 134. LEO Pharma Semi-Solid Dosage Form Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 135. LEO Pharma Semi-Solid Dosage Form Product Portfolio Table 136. LEO Pharma Recent Development Table 137. Mylan N.V. Company Information Table 138. Mylan N.V. Business Overview Table 139. Mylan N.V. Semi-Solid Dosage Form Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 140. Mylan N.V. Semi-Solid Dosage Form Product Portfolio Table 141. Mylan N.V. Recent Development Table 142. Novartis AG Company Information Table 143. Novartis AG Business Overview Table 144. Novartis AG Semi-Solid Dosage Form Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 145. Novartis AG Semi-Solid Dosage Form Product Portfolio Table 146. Novartis AG Recent Development Table 147. Perrigo Pharma Company Information Table 148. Perrigo Pharma Business Overview Table 149. Perrigo Pharma Semi-Solid Dosage Form Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 150. Perrigo Pharma Semi-Solid Dosage Form Product Portfolio Table 151. Perrigo Pharma Recent Development Table 152. Taro Pharmaceutical Industries Ltd. Company Information Table 153. Taro Pharmaceutical Industries Ltd. Business Overview Table 154. Taro Pharmaceutical Industries Ltd. Semi-Solid Dosage Form Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 155. Taro Pharmaceutical Industries Ltd. Semi-Solid Dosage Form Product Portfolio Table 156. Taro Pharmaceutical Industries Ltd. Recent Development Table 157. Teligent Pharma Company Information Table 158. Teligent Pharma Business Overview Table 159. Teligent Pharma Semi-Solid Dosage Form Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 160. Teligent Pharma Semi-Solid Dosage Form Product Portfolio Table 161. Teligent Pharma Recent Development Table 162. Bayer AG Company Information Table 163. Bayer AG Business Overview Table 164. Bayer AG Semi-Solid Dosage Form Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 165. Bayer AG Semi-Solid Dosage Form Product Portfolio Table 166. Bayer AG Recent Development Table 167. GlaxoSmithKline plc Company Information Table 168. GlaxoSmithKline plc Business Overview Table 169. GlaxoSmithKline plc Semi-Solid Dosage Form Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 170. GlaxoSmithKline plc Semi-Solid Dosage Form Product Portfolio Table 171. GlaxoSmithKline plc Recent Development Table 172. Merck & Co Company Information Table 173. Merck & Co Business Overview Table 174. Merck & Co Semi-Solid Dosage Form Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 175. Merck & Co Semi-Solid Dosage Form Product Portfolio Table 176. Merck & Co Recent Development Table 177. Johnson & Johnson Company Information Table 178. Johnson & Johnson Business Overview Table 179. Johnson & Johnson Semi-Solid Dosage Form Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 180. Johnson & Johnson Semi-Solid Dosage Form Product Portfolio Table 181. Johnson & Johnson Recent Development Table 182. Nestlé SA Company Information Table 183. Nestlé SA Business Overview Table 184. Nestlé SA Semi-Solid Dosage Form Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 185. Nestlé SA Semi-Solid Dosage Form Product Portfolio Table 186. Nestlé SA Recent Development Table 187. Sun Pharmaceuticals Company Information Table 188. Sun Pharmaceuticals Business Overview Table 189. Sun Pharmaceuticals Semi-Solid Dosage Form Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 190. Sun Pharmaceuticals Semi-Solid Dosage Form Product Portfolio Table 191. Sun Pharmaceuticals Recent Development Table 192. Key Raw Materials Table 193. Raw Materials Key Suppliers Table 194. Semi-Solid Dosage Form Distributors List Table 195. Semi-Solid Dosage Form Customers List Table 196. Research Programs/Design for This Report Table 197. Authors List of This Report Table 198. Secondary Sources Table 199. Primary Sources List of Figures Figure 1. Semi-Solid Dosage Form Product Image Figure 2. Global Semi-Solid Dosage Form Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Semi-Solid Dosage Form Sales Value (2021-2032) & (US$ Million) Figure 4. Global Semi-Solid Dosage Form Sales (2021-2032) & (K Units) Figure 5. Global Semi-Solid Dosage Form Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Semi-Solid Dosage Form Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Ointments Image Figure 10. Gels Image Figure 11. Others Image Figure 12. Global Semi-Solid Dosage Form Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 13. Global Semi-Solid Dosage Form Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global Semi-Solid Dosage Form Sales Volume Share by Type (2021-2032) Figure 15. Global Semi-Solid Dosage Form Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Semi-Solid Dosage Form Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Semi-Solid Dosage Form Sales Value Share by Type (2021-2032) Figure 18. Nasal Cavity Image Figure 19. Skin Image Figure 20. Vaginal Cavity Image Figure 21. Rectal Cavity Image Figure 22. Others Image Figure 23. Global Semi-Solid Dosage Form Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 24. Global Semi-Solid Dosage Form Sales Volume Share 2021 VS 2025 VS 2032 Figure 25. Global Semi-Solid Dosage Form Sales Volume Share by Application (2021-2032) Figure 26. Global Semi-Solid Dosage Form Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 27. Global Semi-Solid Dosage Form Sales Value Share 2021 VS 2025 VS 2032 Figure 28. Global Semi-Solid Dosage Form Sales Value Share by Application (2021-2032) Figure 29. Global Semi-Solid Dosage Form Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 30. Global Semi-Solid Dosage Form Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 31. Global Semi-Solid Dosage Form Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 32. Global Semi-Solid Dosage Form Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 33. North America Semi-Solid Dosage Form Sales Value (2021-2032) & (US$ Million) Figure 34. North America Semi-Solid Dosage Form Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Europe Semi-Solid Dosage Form Sales Value (2021-2032) & (US$ Million) Figure 36. Europe Semi-Solid Dosage Form Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Asia-Pacific Semi-Solid Dosage Form Sales Value (2021-2032) & (US$ Million) Figure 38. Asia-Pacific Semi-Solid Dosage Form Sales Value Share by Country (%), 2025 VS 2032 Figure 39. South America Semi-Solid Dosage Form Sales Value (2021-2032) & (US$ Million) Figure 40. South America Semi-Solid Dosage Form Sales Value Share by Country (%), 2025 VS 2032 Figure 41. Middle East & Africa Semi-Solid Dosage Form Sales Value (2021-2032) & (US$ Million) Figure 42. Middle East & Africa Semi-Solid Dosage Form Sales Value Share by Country (%), 2025 VS 2032 Figure 43. USA Semi-Solid Dosage Form Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. USA Semi-Solid Dosage Form Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. USA Semi-Solid Dosage Form Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Canada Semi-Solid Dosage Form Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Canada Semi-Solid Dosage Form Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Canada Semi-Solid Dosage Form Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Mexico Semi-Solid Dosage Form Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Mexico Semi-Solid Dosage Form Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Mexico Semi-Solid Dosage Form Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Germany Semi-Solid Dosage Form Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Germany Semi-Solid Dosage Form Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Germany Semi-Solid Dosage Form Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. France Semi-Solid Dosage Form Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. France Semi-Solid Dosage Form Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. France Semi-Solid Dosage Form Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. U.K. Semi-Solid Dosage Form Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. U.K. Semi-Solid Dosage Form Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. U.K. Semi-Solid Dosage Form Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Italy Semi-Solid Dosage Form Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Italy Semi-Solid Dosage Form Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Italy Semi-Solid Dosage Form Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Spain Semi-Solid Dosage Form Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Spain Semi-Solid Dosage Form Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Spain Semi-Solid Dosage Form Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Russia Semi-Solid Dosage Form Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Russia Semi-Solid Dosage Form Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Russia Semi-Solid Dosage Form Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Netherlands Semi-Solid Dosage Form Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Netherlands Semi-Solid Dosage Form Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Netherlands Semi-Solid Dosage Form Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. Nordic Countries Semi-Solid Dosage Form Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. Nordic Countries Semi-Solid Dosage Form Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. Nordic Countries Semi-Solid Dosage Form Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. China Semi-Solid Dosage Form Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. China Semi-Solid Dosage Form Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. China Semi-Solid Dosage Form Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Japan Semi-Solid Dosage Form Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Japan Semi-Solid Dosage Form Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Japan Semi-Solid Dosage Form Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. South Korea Semi-Solid Dosage Form Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. South Korea Semi-Solid Dosage Form Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. South Korea Semi-Solid Dosage Form Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. India Semi-Solid Dosage Form Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. India Semi-Solid Dosage Form Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. India Semi-Solid Dosage Form Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Australia Semi-Solid Dosage Form Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Australia Semi-Solid Dosage Form Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Australia Semi-Solid Dosage Form Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Southeast Asia Semi-Solid Dosage Form Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Southeast Asia Semi-Solid Dosage Form Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Southeast Asia Semi-Solid Dosage Form Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Brazil Semi-Solid Dosage Form Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Brazil Semi-Solid Dosage Form Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Brazil Semi-Solid Dosage Form Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Argentina Semi-Solid Dosage Form Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Argentina Semi-Solid Dosage Form Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Argentina Semi-Solid Dosage Form Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Chile Semi-Solid Dosage Form Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Chile Semi-Solid Dosage Form Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Chile Semi-Solid Dosage Form Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Colombia Semi-Solid Dosage Form Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Colombia Semi-Solid Dosage Form Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Colombia Semi-Solid Dosage Form Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Peru Semi-Solid Dosage Form Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Peru Semi-Solid Dosage Form Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Peru Semi-Solid Dosage Form Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Semi-Solid Dosage Form Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Saudi Arabia Semi-Solid Dosage Form Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Saudi Arabia Semi-Solid Dosage Form Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Israel Semi-Solid Dosage Form Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Israel Arabia Semi-Solid Dosage Form Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Israel Arabia Semi-Solid Dosage Form Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. UAE Semi-Solid Dosage Form Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. UAE Semi-Solid Dosage Form Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. UAE Semi-Solid Dosage Form Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Turkey Semi-Solid Dosage Form Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Turkey Semi-Solid Dosage Form Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Turkey Semi-Solid Dosage Form Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Iran Semi-Solid Dosage Form Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Iran Semi-Solid Dosage Form Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Iran Semi-Solid Dosage Form Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Egypt Semi-Solid Dosage Form Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 125. Egypt Semi-Solid Dosage Form Sales Value Share by Type, 2025 VS 2032 & (%) Figure 126. Egypt Semi-Solid Dosage Form Sales Value Share by Application, 2025 VS 2032 & (%) Figure 127. Semi-Solid Dosage Form Value Chain Figure 128. Manufacturing Cost Structure Figure 129. Semi-Solid Dosage Form Sales Mode & Process Figure 130. Direct Comparison with Distribution Share Figure 131. Distributors Profiles Figure 132. Years Considered Figure 133. Research Process Figure 134. Key Executives Interviewed

Scope & coverage.

Types
  • Ointments
  • Gels
  • Others
Applications
  • Nasal Cavity
  • Skin
  • Vaginal Cavity
  • Rectal Cavity
  • Others
Companies covered
  • Aclaris Therapeutics, Inc.
  • Akorn Inc. (US)
  • Allergan plc
  • Almirall, S.A
  • Bausch Health Companies
  • Biofrontera, Inc.
  • Cipla Ltd
  • Crescita Therapeutics Inc.
  • Crown Laboratories Inc.
  • Encore Dermatology, Inc.
  • Glenmark Pharmaceuticals
  • Hisamitsu Pharmaceutical
  • Ingenus Pharmaceuticals
  • LEO Pharma
  • Mylan N.V.
  • Novartis AG
  • Perrigo Pharma
  • Taro Pharmaceutical Industries Ltd.
  • Teligent Pharma
  • Bayer AG
  • GlaxoSmithKline plc
  • Merck & Co
  • Johnson & Johnson
  • Nestlé SA
  • Sun Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Semi-Solid Dosage Form Sales Value (2021-2032)
  4. 1.2.2 Global Semi-Solid Dosage Form Sales Volume (2021-2032)
  5. 1.2.3 Global Semi-Solid Dosage Form Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Semi-Solid Dosage Form Market Dynamics
  1. 2.1 Semi-Solid Dosage Form Industry Trends
  2. 2.2 Semi-Solid Dosage Form Industry Drivers
  3. 2.3 Semi-Solid Dosage Form Industry Opportunities and Challenges
  4. 2.4 Semi-Solid Dosage Form Industry Restraints
3 Semi-Solid Dosage Form Market by Company
  1. 3.1 Global Semi-Solid Dosage Form Company Revenue Ranking in 2025
  2. 3.2 Global Semi-Solid Dosage Form Revenue by Company (2021-2026)
  3. 3.3 Global Semi-Solid Dosage Form Sales Volume by Company (2021-2026)
  4. 3.4 Global Semi-Solid Dosage Form Average Price by Company (2021-2026)
  5. 3.5 Global Semi-Solid Dosage Form Company Ranking (2024-2026)
  6. 3.6 Global Semi-Solid Dosage Form Company Manufacturing Base and Headquarters
  7. 3.7 Global Semi-Solid Dosage Form Company Product Type and Application
  8. 3.8 Global Semi-Solid Dosage Form Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Semi-Solid Dosage Form Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Semi-Solid Dosage Form Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Semi-Solid Dosage Form Market by Type
  1. 4.1 Semi-Solid Dosage Form Type Introduction
  2. 4.1.1 Ointments
  3. 4.1.2 Gels
  4. 4.1.3 Others
  5. 4.2 Global Semi-Solid Dosage Form Sales Volume by Type
  6. 4.2.1 Global Semi-Solid Dosage Form Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Semi-Solid Dosage Form Sales Volume by Type (2021-2032)
  8. 4.2.3 Global Semi-Solid Dosage Form Sales Volume Share by Type (2021-2032)
  9. 4.3 Global Semi-Solid Dosage Form Sales Value by Type
  10. 4.3.1 Global Semi-Solid Dosage Form Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Semi-Solid Dosage Form Sales Value by Type (2021-2032)
  12. 4.3.3 Global Semi-Solid Dosage Form Sales Value Share by Type (2021-2032)
5 Semi-Solid Dosage Form Market by Application
  1. 5.1 Semi-Solid Dosage Form Application Introduction
  2. 5.1.1 Nasal Cavity
  3. 5.1.2 Skin
  4. 5.1.3 Vaginal Cavity
  5. 5.1.4 Rectal Cavity
  6. 5.1.5 Others
  7. 5.2 Global Semi-Solid Dosage Form Sales Volume by Application
  8. 5.2.1 Global Semi-Solid Dosage Form Sales Volume by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global Semi-Solid Dosage Form Sales Volume by Application (2021-2032)
  10. 5.2.3 Global Semi-Solid Dosage Form Sales Volume Share by Application (2021-2032)
  11. 5.3 Global Semi-Solid Dosage Form Sales Value by Application
  12. 5.3.1 Global Semi-Solid Dosage Form Sales Value by Application (2021 VS 2025 VS 2032)
  13. 5.3.2 Global Semi-Solid Dosage Form Sales Value by Application (2021-2032)
  14. 5.3.3 Global Semi-Solid Dosage Form Sales Value Share by Application (2021-2032)
6 Semi-Solid Dosage Form Regional Sales and Value Analysis
  1. 6.1 Global Semi-Solid Dosage Form Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Semi-Solid Dosage Form Sales by Region (2021-2032)
  3. 6.2.1 Global Semi-Solid Dosage Form Sales by Region: 2021-2026
  4. 6.2.2 Global Semi-Solid Dosage Form Sales by Region (2027-2032)
  5. 6.3 Global Semi-Solid Dosage Form Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Semi-Solid Dosage Form Sales Value by Region (2021-2032)
  7. 6.4.1 Global Semi-Solid Dosage Form Sales Value by Region: 2021-2026
  8. 6.4.2 Global Semi-Solid Dosage Form Sales Value by Region (2027-2032)
  9. 6.5 Global Semi-Solid Dosage Form Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Semi-Solid Dosage Form Sales Value (2021-2032)
  12. 6.6.2 North America Semi-Solid Dosage Form Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Semi-Solid Dosage Form Sales Value (2021-2032)
  15. 6.7.2 Europe Semi-Solid Dosage Form Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Semi-Solid Dosage Form Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Semi-Solid Dosage Form Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Semi-Solid Dosage Form Sales Value (2021-2032)
  21. 6.9.2 South America Semi-Solid Dosage Form Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Semi-Solid Dosage Form Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Semi-Solid Dosage Form Sales Value Share by Country, 2025 VS 2032
7 Semi-Solid Dosage Form Country-level Sales and Value Analysis
  1. 7.1 Global Semi-Solid Dosage Form Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Semi-Solid Dosage Form Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Semi-Solid Dosage Form Sales by Country (2021-2032)
  4. 7.3.1 Global Semi-Solid Dosage Form Sales by Country (2021-2026)
  5. 7.3.2 Global Semi-Solid Dosage Form Sales by Country (2027-2032)
  6. 7.4 Global Semi-Solid Dosage Form Sales Value by Country (2021-2032)
  7. 7.4.1 Global Semi-Solid Dosage Form Sales Value by Country (2021-2026)
  8. 7.4.2 Global Semi-Solid Dosage Form Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Semi-Solid Dosage Form Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Semi-Solid Dosage Form Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Semi-Solid Dosage Form Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Semi-Solid Dosage Form Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Semi-Solid Dosage Form Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Semi-Solid Dosage Form Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Semi-Solid Dosage Form Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Semi-Solid Dosage Form Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Semi-Solid Dosage Form Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Semi-Solid Dosage Form Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Semi-Solid Dosage Form Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Semi-Solid Dosage Form Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Semi-Solid Dosage Form Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Semi-Solid Dosage Form Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Semi-Solid Dosage Form Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Semi-Solid Dosage Form Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Semi-Solid Dosage Form Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Semi-Solid Dosage Form Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Semi-Solid Dosage Form Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Semi-Solid Dosage Form Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Semi-Solid Dosage Form Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Semi-Solid Dosage Form Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Semi-Solid Dosage Form Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Semi-Solid Dosage Form Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Semi-Solid Dosage Form Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Semi-Solid Dosage Form Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Semi-Solid Dosage Form Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Semi-Solid Dosage Form Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Semi-Solid Dosage Form Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Semi-Solid Dosage Form Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Semi-Solid Dosage Form Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Semi-Solid Dosage Form Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Semi-Solid Dosage Form Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Semi-Solid Dosage Form Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Semi-Solid Dosage Form Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Semi-Solid Dosage Form Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Semi-Solid Dosage Form Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Semi-Solid Dosage Form Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Semi-Solid Dosage Form Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Semi-Solid Dosage Form Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Semi-Solid Dosage Form Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Semi-Solid Dosage Form Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Semi-Solid Dosage Form Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Semi-Solid Dosage Form Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Semi-Solid Dosage Form Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Semi-Solid Dosage Form Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Semi-Solid Dosage Form Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Semi-Solid Dosage Form Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Semi-Solid Dosage Form Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Semi-Solid Dosage Form Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Semi-Solid Dosage Form Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Semi-Solid Dosage Form Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Semi-Solid Dosage Form Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Semi-Solid Dosage Form Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Semi-Solid Dosage Form Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Semi-Solid Dosage Form Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Semi-Solid Dosage Form Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Semi-Solid Dosage Form Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Semi-Solid Dosage Form Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Semi-Solid Dosage Form Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Semi-Solid Dosage Form Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Semi-Solid Dosage Form Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Semi-Solid Dosage Form Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Semi-Solid Dosage Form Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Semi-Solid Dosage Form Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Semi-Solid Dosage Form Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Semi-Solid Dosage Form Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Semi-Solid Dosage Form Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Semi-Solid Dosage Form Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Semi-Solid Dosage Form Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Semi-Solid Dosage Form Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Semi-Solid Dosage Form Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Semi-Solid Dosage Form Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Semi-Solid Dosage Form Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Semi-Solid Dosage Form Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Semi-Solid Dosage Form Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Semi-Solid Dosage Form Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Semi-Solid Dosage Form Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Semi-Solid Dosage Form Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Semi-Solid Dosage Form Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Semi-Solid Dosage Form Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Semi-Solid Dosage Form Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Semi-Solid Dosage Form Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Semi-Solid Dosage Form Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Aclaris Therapeutics, Inc.
  2. 8.1.1 Aclaris Therapeutics, Inc. Company Information
  3. 8.1.2 Aclaris Therapeutics, Inc. Business Overview
  4. 8.1.3 Aclaris Therapeutics, Inc. Semi-Solid Dosage Form Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Aclaris Therapeutics, Inc. Semi-Solid Dosage Form Product Portfolio
  6. 8.1.5 Aclaris Therapeutics, Inc. Recent Developments
  7. 8.2 Akorn Inc. (US)
  8. 8.2.1 Akorn Inc. (US) Company Information
  9. 8.2.2 Akorn Inc. (US) Business Overview
  10. 8.2.3 Akorn Inc. (US) Semi-Solid Dosage Form Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Akorn Inc. (US) Semi-Solid Dosage Form Product Portfolio
  12. 8.2.5 Akorn Inc. (US) Recent Developments
  13. 8.3 Allergan plc
  14. 8.3.1 Allergan plc Company Information
  15. 8.3.2 Allergan plc Business Overview
  16. 8.3.3 Allergan plc Semi-Solid Dosage Form Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Allergan plc Semi-Solid Dosage Form Product Portfolio
  18. 8.3.5 Allergan plc Recent Developments
  19. 8.4 Almirall, S.A
  20. 8.4.1 Almirall, S.A Company Information
  21. 8.4.2 Almirall, S.A Business Overview
  22. 8.4.3 Almirall, S.A Semi-Solid Dosage Form Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Almirall, S.A Semi-Solid Dosage Form Product Portfolio
  24. 8.4.5 Almirall, S.A Recent Developments
  25. 8.5 Bausch Health Companies
  26. 8.5.1 Bausch Health Companies Company Information
  27. 8.5.2 Bausch Health Companies Business Overview
  28. 8.5.3 Bausch Health Companies Semi-Solid Dosage Form Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Bausch Health Companies Semi-Solid Dosage Form Product Portfolio
  30. 8.5.5 Bausch Health Companies Recent Developments
  31. 8.6 Biofrontera, Inc.
  32. 8.6.1 Biofrontera, Inc. Company Information
  33. 8.6.2 Biofrontera, Inc. Business Overview
  34. 8.6.3 Biofrontera, Inc. Semi-Solid Dosage Form Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Biofrontera, Inc. Semi-Solid Dosage Form Product Portfolio
  36. 8.6.5 Biofrontera, Inc. Recent Developments
  37. 8.7 Cipla Ltd
  38. 8.7.1 Cipla Ltd Company Information
  39. 8.7.2 Cipla Ltd Business Overview
  40. 8.7.3 Cipla Ltd Semi-Solid Dosage Form Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Cipla Ltd Semi-Solid Dosage Form Product Portfolio
  42. 8.7.5 Cipla Ltd Recent Developments
  43. 8.8 Crescita Therapeutics Inc.
  44. 8.8.1 Crescita Therapeutics Inc. Company Information
  45. 8.8.2 Crescita Therapeutics Inc. Business Overview
  46. 8.8.3 Crescita Therapeutics Inc. Semi-Solid Dosage Form Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Crescita Therapeutics Inc. Semi-Solid Dosage Form Product Portfolio
  48. 8.8.5 Crescita Therapeutics Inc. Recent Developments
  49. 8.9 Crown Laboratories Inc.
  50. 8.9.1 Crown Laboratories Inc. Company Information
  51. 8.9.2 Crown Laboratories Inc. Business Overview
  52. 8.9.3 Crown Laboratories Inc. Semi-Solid Dosage Form Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Crown Laboratories Inc. Semi-Solid Dosage Form Product Portfolio
  54. 8.9.5 Crown Laboratories Inc. Recent Developments
  55. 8.10 Encore Dermatology, Inc.
  56. 8.10.1 Encore Dermatology, Inc. Company Information
  57. 8.10.2 Encore Dermatology, Inc. Business Overview
  58. 8.10.3 Encore Dermatology, Inc. Semi-Solid Dosage Form Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Encore Dermatology, Inc. Semi-Solid Dosage Form Product Portfolio
  60. 8.10.5 Encore Dermatology, Inc. Recent Developments
  61. 8.11 Glenmark Pharmaceuticals
  62. 8.11.1 Glenmark Pharmaceuticals Company Information
  63. 8.11.2 Glenmark Pharmaceuticals Business Overview
  64. 8.11.3 Glenmark Pharmaceuticals Semi-Solid Dosage Form Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Glenmark Pharmaceuticals Semi-Solid Dosage Form Product Portfolio
  66. 8.11.5 Glenmark Pharmaceuticals Recent Developments
  67. 8.12 Hisamitsu Pharmaceutical
  68. 8.12.1 Hisamitsu Pharmaceutical Company Information
  69. 8.12.2 Hisamitsu Pharmaceutical Business Overview
  70. 8.12.3 Hisamitsu Pharmaceutical Semi-Solid Dosage Form Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Hisamitsu Pharmaceutical Semi-Solid Dosage Form Product Portfolio
  72. 8.12.5 Hisamitsu Pharmaceutical Recent Developments
  73. 8.13 Ingenus Pharmaceuticals
  74. 8.13.1 Ingenus Pharmaceuticals Company Information
  75. 8.13.2 Ingenus Pharmaceuticals Business Overview
  76. 8.13.3 Ingenus Pharmaceuticals Semi-Solid Dosage Form Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Ingenus Pharmaceuticals Semi-Solid Dosage Form Product Portfolio
  78. 8.13.5 Ingenus Pharmaceuticals Recent Developments
  79. 8.14 LEO Pharma
  80. 8.14.1 LEO Pharma Company Information
  81. 8.14.2 LEO Pharma Business Overview
  82. 8.14.3 LEO Pharma Semi-Solid Dosage Form Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 LEO Pharma Semi-Solid Dosage Form Product Portfolio
  84. 8.14.5 LEO Pharma Recent Developments
  85. 8.15 Mylan N.V.
  86. 8.15.1 Mylan N.V. Company Information
  87. 8.15.2 Mylan N.V. Business Overview
  88. 8.15.3 Mylan N.V. Semi-Solid Dosage Form Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Mylan N.V. Semi-Solid Dosage Form Product Portfolio
  90. 8.15.5 Mylan N.V. Recent Developments
  91. 8.16 Novartis AG
  92. 8.16.1 Novartis AG Company Information
  93. 8.16.2 Novartis AG Business Overview
  94. 8.16.3 Novartis AG Semi-Solid Dosage Form Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 Novartis AG Semi-Solid Dosage Form Product Portfolio
  96. 8.16.5 Novartis AG Recent Developments
  97. 8.17 Perrigo Pharma
  98. 8.17.1 Perrigo Pharma Company Information
  99. 8.17.2 Perrigo Pharma Business Overview
  100. 8.17.3 Perrigo Pharma Semi-Solid Dosage Form Sales, Value and Gross Margin (2021-2026)
  101. 8.17.4 Perrigo Pharma Semi-Solid Dosage Form Product Portfolio
  102. 8.17.5 Perrigo Pharma Recent Developments
  103. 8.18 Taro Pharmaceutical Industries Ltd.
  104. 8.18.1 Taro Pharmaceutical Industries Ltd. Company Information
  105. 8.18.2 Taro Pharmaceutical Industries Ltd. Business Overview
  106. 8.18.3 Taro Pharmaceutical Industries Ltd. Semi-Solid Dosage Form Sales, Value and Gross Margin (2021-2026)
  107. 8.18.4 Taro Pharmaceutical Industries Ltd. Semi-Solid Dosage Form Product Portfolio
  108. 8.18.5 Taro Pharmaceutical Industries Ltd. Recent Developments
  109. 8.19 Teligent Pharma
  110. 8.19.1 Teligent Pharma Company Information
  111. 8.19.2 Teligent Pharma Business Overview
  112. 8.19.3 Teligent Pharma Semi-Solid Dosage Form Sales, Value and Gross Margin (2021-2026)
  113. 8.19.4 Teligent Pharma Semi-Solid Dosage Form Product Portfolio
  114. 8.19.5 Teligent Pharma Recent Developments
  115. 8.20 Bayer AG
  116. 8.20.1 Bayer AG Company Information
  117. 8.20.2 Bayer AG Business Overview
  118. 8.20.3 Bayer AG Semi-Solid Dosage Form Sales, Value and Gross Margin (2021-2026)
  119. 8.20.4 Bayer AG Semi-Solid Dosage Form Product Portfolio
  120. 8.20.5 Bayer AG Recent Developments
  121. 8.21 GlaxoSmithKline plc
  122. 8.21.1 GlaxoSmithKline plc Company Information
  123. 8.21.2 GlaxoSmithKline plc Business Overview
  124. 8.21.3 GlaxoSmithKline plc Semi-Solid Dosage Form Sales, Value and Gross Margin (2021-2026)
  125. 8.21.4 GlaxoSmithKline plc Semi-Solid Dosage Form Product Portfolio
  126. 8.21.5 GlaxoSmithKline plc Recent Developments
  127. 8.22 Merck & Co
  128. 8.22.1 Merck & Co Company Information
  129. 8.22.2 Merck & Co Business Overview
  130. 8.22.3 Merck & Co Semi-Solid Dosage Form Sales, Value and Gross Margin (2021-2026)
  131. 8.22.4 Merck & Co Semi-Solid Dosage Form Product Portfolio
  132. 8.22.5 Merck & Co Recent Developments
  133. 8.23 Johnson & Johnson
  134. 8.23.1 Johnson & Johnson Company Information
  135. 8.23.2 Johnson & Johnson Business Overview
  136. 8.23.3 Johnson & Johnson Semi-Solid Dosage Form Sales, Value and Gross Margin (2021-2026)
  137. 8.23.4 Johnson & Johnson Semi-Solid Dosage Form Product Portfolio
  138. 8.23.5 Johnson & Johnson Recent Developments
  139. 8.24 Nestlé SA
  140. 8.24.1 Nestlé SA Company Information
  141. 8.24.2 Nestlé SA Business Overview
  142. 8.24.3 Nestlé SA Semi-Solid Dosage Form Sales, Value and Gross Margin (2021-2026)
  143. 8.24.4 Nestlé SA Semi-Solid Dosage Form Product Portfolio
  144. 8.24.5 Nestlé SA Recent Developments
  145. 8.25 Sun Pharmaceuticals
  146. 8.25.1 Sun Pharmaceuticals Company Information
  147. 8.25.2 Sun Pharmaceuticals Business Overview
  148. 8.25.3 Sun Pharmaceuticals Semi-Solid Dosage Form Sales, Value and Gross Margin (2021-2026)
  149. 8.25.4 Sun Pharmaceuticals Semi-Solid Dosage Form Product Portfolio
  150. 8.25.5 Sun Pharmaceuticals Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Semi-Solid Dosage Form Value Chain Analysis
  2. 9.1.1 Semi-Solid Dosage Form Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Semi-Solid Dosage Form Sales Mode & Process
  6. 9.2 Semi-Solid Dosage Form Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Semi-Solid Dosage Form Distributors
  9. 9.2.3 Semi-Solid Dosage Form Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst